{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T22:59:00Z","timestamp":1788908340034,"version":"build-2803163510"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2025,8,12]],"date-time":"2025-08-12T00:00:00Z","timestamp":1754956800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,8,12]],"date-time":"2025-08-12T00:00:00Z","timestamp":1754956800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Medical Products Agency"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Drug Investig"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1007\/s40261-025-01466-3","type":"journal-article","created":{"date-parts":[[2025,8,12]],"date-time":"2025-08-12T15:29:20Z","timestamp":1755012560000},"page":"665-675","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Spontaneous Reports of Adverse Reactions with Fatal Outcomes After COVID-19 Vaccination During the National Vaccination Campaign in Sweden"],"prefix":"10.1007","volume":"45","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-4681-5180","authenticated-orcid":false,"given":"Marja-Leena","family":"Nurminen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-9431-4319","authenticated-orcid":false,"given":"Per","family":"Lindemo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2337-3371","authenticated-orcid":false,"given":"Anders","family":"Sundstr\u00f6m","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1738-0834","authenticated-orcid":false,"given":"Bj\u00f6rn","family":"Zethelius","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-3496-8922","authenticated-orcid":false,"given":"Maria","family":"Larsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7631-7376","authenticated-orcid":false,"given":"Sofia","family":"Attelind","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6812-0971","authenticated-orcid":false,"given":"Nicklas","family":"Pihlstr\u00f6m","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0654-4530","authenticated-orcid":false,"given":"Rickard","family":"Ljung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-6603-224X","authenticated-orcid":false,"given":"Veronica","family":"Arthurson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,12]]},"reference":[{"key":"1466_CR1","unstructured":"World Health Organization. Coronavirus disease (COVID-19) pandemic. who.int. https:\/\/www.who.int\/europe\/emergencies\/situations\/covid-19. Accessed 11 June 2025."},{"key":"1466_CR2","unstructured":"The Public Health Agency of Sweden. Public health data [in Swedish]. https:\/\/fohm-app.folkhalsomyndigheten.se\/Folkhalsodata\/pxweb\/sv\/A_Folkhalsodata\/. Accessed 11 June 2025."},{"key":"1466_CR3","unstructured":"The National Board of Health and Welfare. The state of healthcare: Covid-19 [in Swedish]. https:\/\/www.socialstyrelsen.se\/statistik-och-data\/statistik\/alla-statistikamnen\/lagesbild-covid-19-influensa-och-rs-statistik\/. Accessed 11 June 2025."},{"key":"1466_CR4","unstructured":"The National Board of Health and Welfare. Statistical database for causes of death [in Swedish]. https:\/\/sdb.socialstyrelsen.se\/if_dor\/val.aspx. Accessed 11 June 2025."},{"key":"1466_CR5","unstructured":"European Medicines Agency (EMA). Comirnaty. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/comirnaty.. Accessed 11 June 2025."},{"key":"1466_CR6","unstructured":"European Medicines Agency (EMA). Spikevax (previously COVID-19 vaccine Moderna). https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/spikevax. Accessed 11 June 2025."},{"key":"1466_CR7","unstructured":"European Medicines Agency (EMA). Vaxzevria (previously COVID-19 Vaccine AstraZeneca). https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/vaxzevria. Accessed 11 June 2025."},{"key":"1466_CR8","unstructured":"European Medicines Agency (EMA). Nuvaxovid.  https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/nuvaxovid. Accessed 11 June 2025."},{"issue":"8","key":"1466_CR9","doi-asserted-by":"publisher","first-page":"1574","DOI":"10.1016\/j.jamda.2021.06.010","volume":"22","author":"M Ballin","year":"2021","unstructured":"Ballin M, Bergman J, Kivipelto M, Nordstr\u00f6m A, Nordstr\u00f6m P. Excess mortality after COVID-19 in Swedish long-term care facilities. J Am Med Dir Assoc. 2021;22(8):1574\u201380.","journal-title":"J Am Med Dir Assoc"},{"issue":"4","key":"1466_CR10","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1111\/joim.13522","volume":"292","author":"A Rosengren","year":"2022","unstructured":"Rosengren A, Lundberg CE, S\u00f6derberg M, Santosa A, Edqvist J, Lindgren M, et al. Severe COVID-19 in people 55 and older during the first year of the pandemic in Sweden. J Intern Med. 2022;292(4):641\u201353. https:\/\/doi.org\/10.1111\/joim.13522.","journal-title":"J Intern Med"},{"key":"1466_CR11","unstructured":"EDCD. Overview of the implementation of COVID-19 vaccination strategies and deployment plans in the EU\/EEA. https:\/\/www.edcd.europa.eu\/sites\/default\/files\/documents\/Overview-of-the-implementation-of-COVID-19-vaccination-strategies-anddeploymentplans-14-June-2021.pdf. Accessed 11 June 2025."},{"issue":"2","key":"1466_CR12","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1093\/oxfordjournals.aje.a112795","volume":"110","author":"LB Schonberger","year":"1979","unstructured":"Schonberger LB, Bregman DJ, Sullivan-Bolyai JZ, Keenlyside RA, Ziegler DW, Retailliau HF, et al. Guillain\u2013Barre syndrome following vaccination in the national influenza program, United States, 1976\u20131977. Am J Epidemiol. 1979;110(2):105\u201323. https:\/\/doi.org\/10.1093\/oxfordjournals.aje.a112795.","journal-title":"Am J Epidemiol"},{"issue":"8","key":"1466_CR13","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1002\/pds.4788","volume":"28","author":"F Granath","year":"2019","unstructured":"Granath F, Gedeborg R, Smedje H, Felthelius N. Change in risk for narcolepsy over time and impact of definition of onset date following vaccination with AS03 adjuvanted pandemic A\/H1N1 influenza vaccine (Pandemrix) during the 2009 H1N1 influenza pandemic. Pharmacoepidemiol Drug Saf. 2019;28(8):1045\u201353.","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"1466_CR14","unstructured":"Swedish Medical Products Agency\u2019s regulation (LVFS 2012:14) on pharmacovigilance of medicinal products for human use, 19\u00a7. [in Swedish]. lvfs-2012-14-konsoliderad.pdf. Accessed 11 June 2025. https:\/\/www.lakemedelsverket.se\/globalassets\/dokument\/lagar-och-regler\/hslf-fs\/lvfs-2012-14-konsoliderad.pdf"},{"issue":"3","key":"1466_CR15","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1007\/s40264-023-01275-7","volume":"46","author":"KM K\u00e4lkner","year":"2023","unstructured":"K\u00e4lkner KM, Sundstr\u00f6m A, Nurminen M-L, Larsson M, Ljung R, Arthurson V. Optimizing safety surveillance for COVID-19 vaccines at the Swedish Medical Products Agency. Drug Saf. 2023;46(3):319\u201321. https:\/\/doi.org\/10.1007\/s40264-023-01275-7.","journal-title":"Drug Saf"},{"key":"1466_CR16","doi-asserted-by":"publisher","DOI":"10.48101\/ujms.v126.8136","author":"R Ljung","year":"2021","unstructured":"Ljung R, Sundstr\u00f6m A, Gr\u00fcnewald M, Backman C, Feltelius N, Gedeborg R, et al. The profile of the COvid-19 VACcination register SAFEty study in Sweden (CoVacSafe-SE). Upsala J Med Sci. 2021. https:\/\/doi.org\/10.48101\/ujms.v126.8136.","journal-title":"Upsala J Med Sci"},{"key":"1466_CR17","unstructured":"Medical Dictionary for Regulatory Activities (MedDRA). https:\/\/www.meddra.org. Accessed 11 June 2025."},{"key":"1466_CR18","unstructured":"European Medicines Agency (EMA). Guideline on good pharmacovigilance practices (GVP). Module VI: collection, management and submission of reports of suspected adverse reactions to medical products (Rev 2). https:\/\/www.ema.europa.eu\/en\/documents\/other\/european-medicines-agency-policy-access-eudravigilance-data-medicinalproducts-human-use_en.pdf."},{"key":"1466_CR19","unstructured":"European Medicines Agency (EMA). European Medicines Agency policy on access to EudraVigilance data for medicinal products for human use. EV access policy_document_2024 revision 5. https:\/\/www.ema.europa.eu\/en\/human-regulatory-overview\/post-authorisation\/pharmacovigilance-post-authorisation\/goodpharmacovigilance-practices-gvp. Accessed 18 June 2025."},{"key":"1466_CR20","unstructured":"European Medicines Agency (EMA). Guideline on good pharmacovigilance practices (GVP). Module VI Addendum I: duplicate management of suspected adverse reaction reports. Accessed 4 Feb 2025. https:\/\/www.ema.europa.eu\/en\/documents\/regulatory-procedural-guideline\/guideline-good-pharmacovigilance-practices-gvpmodule-vi-addendum-i-duplicate-management-suspected-adverse-reaction-reports_en.pdf"},{"key":"1466_CR21","unstructured":"World Health Organization (WHO). Causality assessment of an adverse event following immunization (AEFI): user manual for the revised WHO classification, 2nd ed., 2019 update. who.int. https:\/\/www.ema.europa.eu\/en\/human-regulatory-overview\/post-authorisation\/pharmacovigilance-post-authorisation\/goodpharmacovigilance-practices-gvp. Accessed 11 June 2025."},{"issue":"7","key":"1466_CR22","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1002\/pds.5605","volume":"32","author":"B Day","year":"2023","unstructured":"Day B, Menschik D, Thompson D, Jankosky C, Su J, Moro P, et al. Reporting rates for VAERS death reports following COVID-19 vaccination, December 14, 2020\u2212November 17, 2021. Pharmacoepidemiol Drug Saf. 2023;32(7):763\u201372. https:\/\/doi.org\/10.1002\/pds.5605.","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"26","key":"1466_CR23","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2024.126368","volume":"42","author":"I Laemmle-Ruff","year":"2024","unstructured":"Laemmle-Ruff I, Fryk JJ, Shenton P, Clothier HJ, Parsons S, Iles L, et al. Detailed review of mortality reported following COVID-19 vaccination in Victoria, Australia: 2021\u20132023. Vaccine. 2024;42(26): 126368. https:\/\/doi.org\/10.1016\/j.vaccine.2024.126368.","journal-title":"Vaccine"},{"key":"1466_CR24","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1016\/j.vaccine.2011.12048","volume":"30","author":"U Heininger","year":"2012","unstructured":"Heininger U, Bachtiar NS, Bahri P, Dana A, Dodoo A, Gidudu J, et al. The concept of vaccination failure. Vaccine. 2012;30:1265\u20138. https:\/\/doi.org\/10.1016\/j.vaccine.2011.12048.","journal-title":"Vaccine"},{"key":"1466_CR25","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1007\/s10654-017-0316-1","volume":"32","author":"HL Brooke","year":"2017","unstructured":"Brooke HL, Talb\u00e4ck M, H\u00f6rnblad J, Johansson LA, Ludvigsson JF, Druid H, et al. The Swedish cause of death register. Eur J Epidemiol. 2017;32:765\u201373. https:\/\/doi.org\/10.1007\/s10654-017-0316-1.","journal-title":"Eur J Epidemiol"},{"issue":"6","key":"1466_CR26","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1056\/NEJMp2313217","volume":"390","author":"HJ Warraich","year":"2024","unstructured":"Warraich HJ, Marston HD, Califf RM. Addressing the challenge of common chronic diseases: a view from the FDA. N Engl J Med. 2024;390(6):490\u20132. https:\/\/doi.org\/10.1056\/NEJMp2313217.","journal-title":"N Engl J Med"},{"issue":"e75","key":"1466_CR27","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1017\/S1463423622000640","volume":"23","author":"L Nilsson","year":"2022","unstructured":"Nilsson L, Andersson C, Kastbom L, Sj\u00f6dahl R. Association between vaccination and preventive routines on COVID-19-related mortality in nursing home facilities: a population-based systematic retrospective chart review. Prim Health Care Res Dev. 2022;23(e75):1\u20137. https:\/\/doi.org\/10.1017\/S1463423622000640.","journal-title":"Prim Health Care Res Dev."},{"issue":"4","key":"1466_CR28","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1093\/eurheartj\/ehz405","volume":"41","author":"SV Konstantinides","year":"2020","unstructured":"Konstantinides SV, Meyer G, Becattini C, Bueno H, Geersing G-J, Harjola V-P, et al. 2019 ESC guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS). Eur Heart J. 2020;41(4):543\u2013603. https:\/\/doi.org\/10.1093\/eurheartj\/ehz405.","journal-title":"Eur Heart J"},{"key":"1466_CR29","doi-asserted-by":"publisher","DOI":"10.1016\/j.jvacX.2024.100571","volume":"21","author":"B Zethelius","year":"2024","unstructured":"Zethelius B, Attelind S, Westman G, Ljung R, Sundstr\u00f6m A. Pulmonary embolism after SARS-CoV-2 vaccination. Vaccine X. 2024;21: 100571. https:\/\/doi.org\/10.1016\/j.jvacX.2024.100571.","journal-title":"Vaccine X."},{"issue":"9","key":"1466_CR30","doi-asserted-by":"publisher","first-page":"1250","DOI":"10.7326\/M22-0988","volume":"175","author":"J Botton","year":"2022","unstructured":"Botton J, Jabagi MJ, Bertrand M, Baricault B, Drouin J, Le Vu S, et al. Risk for myocardial infarction, stroke, and pulmonary embolism following COVID-19 vaccines in adults younger than 75 years in France. Ann Intern Med. 2022;175(9):1250\u20137. https:\/\/doi.org\/10.7326\/M22-0988.","journal-title":"Ann Intern Med"},{"issue":"12","key":"1466_CR31","doi-asserted-by":"publisher","first-page":"1078","DOI":"10.1056\/NEJMoa2110475","volume":"385","author":"N Barda","year":"2021","unstructured":"Barda N, Dagan N, Ben-Shlomo Y, Kepten E, Waxman J, Ohana R, et al. Safety of the BNT162b2 mRNA Covid-19 vaccine in a nationwide setting. N Engl J Med. 2021;385(12):1078\u201390. https:\/\/doi.org\/10.1056\/NEJMoa2110475.","journal-title":"N Engl J Med"},{"issue":"1","key":"1466_CR32","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1001\/jama.2021.21699","volume":"327","author":"MJ Jabagi","year":"2022","unstructured":"Jabagi MJ, Botton J, Bertrand M, Weill A, Farrington P, Zureik M, et al. Myocardial infarction, stroke, and pulmonary embolism after BNT162b2 mRNA COVID-19 vaccine in people aged 75 years or older. JAMA. 2022;327(1):80\u20132. https:\/\/doi.org\/10.1001\/jama.2021.21699.","journal-title":"JAMA"},{"issue":"4","key":"1466_CR33","doi-asserted-by":"publisher","first-page":"541","DOI":"10.7326\/M21-2452","volume":"175","author":"A Hviid","year":"2022","unstructured":"Hviid A, Hansen JV, Thiesson EM, Wohlfahrt J. Association of AZD1222 and BNT162b2 COVID-19 vaccination with thromboembolic and thrombocytopenic events in frontline personnel: a retrospective cohort study. Ann Intern Med. 2022;175(4):541\u20136. https:\/\/doi.org\/10.7326\/M21-2452.","journal-title":"Ann Intern Med"},{"key":"1466_CR34","unstructured":"European Medicines Agency (EMA). AstraZeneca\u2019s COVID-19 vaccine: EMA finds possible link to very rare cases of unusual blood clots with low blood platelets. https:\/\/www.ema.europa.eu\/en\/news\/astrazenecas-covid-19-vaccine-ema-finds-possible-link-very-rare-cases-unusual-blood-clots-low-blood. Accessed 11 June 2025."},{"key":"1466_CR35","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2021-069590","volume":"376","author":"I Katsoularis","year":"2022","unstructured":"Katsoularis I, Fonseca-Rodriguez O, Farrington P, Jerndal H, H\u00e4ggstr\u00f6m Lundevaller E, Sund M, et al. Risks of deep vein thrombosis, pulmonary embolism, and bleeding after covid-19: nationwide self-controlled cases series and matched cohort study. BMJ. 2022;376: e069590. https:\/\/doi.org\/10.1136\/bmj-2021-069590.","journal-title":"BMJ"},{"issue":"5","key":"1466_CR36","doi-asserted-by":"publisher","DOI":"10.1016\/j.rpth.2023.100284","volume":"7","author":"H Sj\u00f6land","year":"2023","unstructured":"Sj\u00f6land H, Lindgren M, Toska T, Hansson P-O, Glise Sandblad K, Alex C, et al. Pulmonary embolism and deep venous thrombosis after COVID-19: long-term risk in a population-based cohort study. Res Pract Thromb Haemost. 2023;7(5): e100284. https:\/\/doi.org\/10.1016\/j.rpth.2023.100284.","journal-title":"Res Pract Thromb Haemost."},{"key":"1466_CR37","doi-asserted-by":"publisher","first-page":"e1465","DOI":"10.1212\/WNL.0000000000200996","volume":"99","author":"M-I Stefanou","year":"2022","unstructured":"Stefanou M-I, Palaiodimou L, de Aguiar de Sousa D, Theodorou A, Bakola E, Katsaros DE, et al. Acute arterial ischemic stroke following COVID-vaccination: a systematic review and meta-analysis. Neurology. 2022;99:e1465\u201374. https:\/\/doi.org\/10.1212\/WNL.0000000000200996.","journal-title":"Neurology"},{"issue":"10300","key":"1466_CR38","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1016\/S0140-6736(21)00896-5","volume":"398","author":"I Katsoularis","year":"2021","unstructured":"Katsoularis I, Fonseca-Rodriguez O, Farrington P, Fors Conolly A-M. Risk of acute myocardial infarction and ischaemic stroke following COVID-19 in Sweden: a self-controlled case series and matched cohort study. Lancet. 2021;398(10300):599\u2013607. https:\/\/doi.org\/10.1016\/S0140-6736(21)00896-5.","journal-title":"Lancet"},{"issue":"22","key":"1466_CR39","doi-asserted-by":"publisher","first-page":"2092","DOI":"10.1056\/NEJMoa2104840","volume":"384","author":"A Greinacher","year":"2021","unstructured":"Greinacher A, Thiele T, Warkentin TE, Weisser K, Kyrie PA, Eichinger S, et al. Thrombotic thrombocytopenia after ChAdOx1 nCov-19 vaccination. N Engl J Med. 2021;384(22):2092\u2013101. https:\/\/doi.org\/10.1056\/NEJMoa2104840.","journal-title":"N Engl J Med"},{"issue":"22","key":"1466_CR40","doi-asserted-by":"publisher","first-page":"2124","DOI":"10.1056\/NEJMoa2104882","volume":"384","author":"NH Schultz","year":"2021","unstructured":"Schultz NH, S\u00f8rvoll IH, Michelsen AE, Munthe LA, Lund-Johansen F, Ahlen MT, et al. Thrombosis and thrombocytopenia after ChAdOx1 nCoV-19 vaccination. N Engl J Med. 2021;384(22):2124\u201330. https:\/\/doi.org\/10.1056\/NEJMoa2104882.","journal-title":"N Engl J Med"},{"issue":"19","key":"1466_CR41","doi-asserted-by":"publisher","first-page":"6126","DOI":"10.3390\/jcm12196126","volume":"12","author":"VAS Dabbiru","year":"2023","unstructured":"Dabbiru VAS, M\u00fcller L, Sch\u00f6nborn L, Greinacher A. Vaccine-induced immune thrombocytopenia and thrombosis (VITT): insights from clinical cases, in vitro studies and murine models. J Clin Med. 2023;12(19):6126. https:\/\/doi.org\/10.3390\/jcm12196126.","journal-title":"J Clin Med"},{"key":"1466_CR42","unstructured":"Public Health Agency of Sweden. What happened and when during pandemic? [in Swedish]. https:\/\/www.folkhalsomyndigheten.se\/smittskydd-beredskap\/utbrott\/utbrottsarkiv\/covid-19-pandemin-2019-2023\/nar-handevad-under-pandemin\/. Accessed 11 June 2025."},{"issue":"4","key":"1466_CR43","doi-asserted-by":"publisher","first-page":"513","DOI":"10.7326\/M21-4502","volume":"175","author":"I See","year":"2022","unstructured":"See I, Lale A, Marquez P, Streiff MB, Wheeler AP, Tepper NK, et al. Case series of thrombosis with thrombocytopenia syndrome after COVID-19 vaccination: United States, December 2020 to August 2021. Ann Intern Med. 2022;175(4):513\u201322. https:\/\/doi.org\/10.7326\/M21-4502.","journal-title":"Ann Intern Med"},{"issue":"6","key":"1466_CR44","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1001\/jamacardio.2022.0583","volume":"7","author":"\u00d8 Karlstad","year":"2022","unstructured":"Karlstad \u00d8, Hovi P, Husby A, H\u00e4rk\u00e4nen T, Selmer RM, Pihlstr\u00f6m N, et al. SARS-CoV-2 vaccination and myocarditis in a nordic cohort study. JAMA Cardiol. 2022;7(6):600\u201312. https:\/\/doi.org\/10.1001\/jamacardio.2022.0583.","journal-title":"JAMA Cardiol."},{"issue":"2","key":"1466_CR45","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1007\/s40264-021-01138-z","volume":"45","author":"RE Ferner","year":"2022","unstructured":"Ferner RE, Stevens RJ, Anton C, Aronson JK. Spontaneous reporting to regulatory authorities of suspected adverse reactions to COVID-19 vaccines over time: the effect of publicity. Drug Saf. 2022;45(2):137\u201344. https:\/\/doi.org\/10.1007\/s40264-021-01138-z.","journal-title":"Drug Saf"},{"issue":"1","key":"1466_CR46","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1007\/s40264-022-01253-5","volume":"46","author":"I Oosterhuis","year":"2023","unstructured":"Oosterhuis I, Scholl J, van Puijenbroek E, Kant A, van Hunsel F. Optimizing safety surveillance for COVID-19 vaccines at the national pharmacovigilance centre Lareb: one year of COVID-19 vaccine experience. Drug Saf. 2023;46(1):65\u201375. https:\/\/doi.org\/10.1007\/s40264-022-01253-5.","journal-title":"Drug Saf"}],"container-title":["Clinical Drug Investigation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-025-01466-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40261-025-01466-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-025-01466-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,10]],"date-time":"2025-09-10T06:59:33Z","timestamp":1757487573000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40261-025-01466-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,12]]},"references-count":46,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["1466"],"URL":"https:\/\/doi.org\/10.1007\/s40261-025-01466-3","relation":{},"ISSN":["1173-2563","1179-1918"],"issn-type":[{"value":"1173-2563","type":"print"},{"value":"1179-1918","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,12]]},"assertion":[{"value":"22 July 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 August 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Open access funding provided by Medical Products Agency. The study was conducted as a pharmacovigilance activity by the Swedish MPA, which is a Swedish Government agency. The study has received no external funding.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Marja-Leena Nurminen, Per Lindemo, Anders Sundstr\u00f6m, Bj\u00f6rn Zethelius, Maria Larsson, Sofia Attelind, Nicklas Pihlstr\u00f6m, Rickard Ljung, and Veronica Arthurson have no conflicts of interest that are directly relevant to the content of this article.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest\/competing interests"}},{"value":"This study was conducted in accordance with the Declaration of Helsinki. The study protocol was approved by the Swedish Ethical Review Authority (2020-06859, 2021-02186).","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The data of this article are not publicly available because of the EMA\u2019s policy of access to EudraVigilance data for medical products for human use in accordance with Regulation (EU) 2016\/679, the General Data Protection Regulation and Regulation (EU) 2018\/1725, and the European Union data protection legislation. For more information, see: .","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"MLN drafted the manuscript and constructed the tables. NP constructed the graphs. MLN, PL, ML, and SA provided the ADR data. AS and NP accomplished the statistics on mortality and hospitalizations due to COVID-19, positive COVID-19 tests, and exposure to COVID-19 vaccines from nationwide healthcare register data. BZ administered the submission. RL and VA supervised the project. All authors reviewed, edited, and approved the final version of the manuscript.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 contributions"}}]}}